New drug combo shows promise in shrinking breast tumors before surgery

NCT ID NCT01723774

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a targeted drug (PD 0332991) to standard hormone therapy (anastrozole) before surgery can better stop breast cancer cell growth in women with early-stage ER+ HER2- breast cancer. About 84 women with stage 2 or 3 disease will receive the combination for several weeks before their operation. The main goal is to see if the tumor's growth marker (Ki67) drops to very low levels, which may lead to better long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS

Contacts and locations

Show contact details

Locations

Mayo Clinic - Rochester

Rochester, Minnesota, 55905, United States
Mayo Clinic - Scottsdale

Scottsdale, Arizona, 85259, United States
University of Alabama

Birmingham, Alabama, 35233, United States
Washington University School of Medicine

St Louis, Missouri, 63122, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.